GlassScriptPhysician profile
Tri Cao Le
NPI 1609286756
$3,653.37
in general payments reported to CMS, 2019-2025
29 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.00 · 2022: $124 · 2023: $358 · 2024: $1,387 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,030 · Food and Beverage: $1,301 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,029.70 |
| Food and Beverage | $1,300.88 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,113.62 | 2024-2025 | |
| Incyte Corporation | $169.22 | 2023-2025 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $164.30 | 2023-2025 | Trodelvy |
| Celgene Corporation | $137.38 | 2022-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $116.31 | 2024-2025 | Jemperli, Ojjaara, Trelegy Ellipta |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $67.47 | 2023-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $67.15 | 2022-2025 | Eliquis, Opdivo |
| Lilly USA, LLC | $66.66 | 2023-2025 | Jaypirca, Verzenio |
| Merck Sharp & Dohme LLC | $60.84 | 2023-2024 | Keytruda, Lynparza |
| Abbvie INC. | $52.62 | 2024 | |
| Eisai INC. | $47.66 | 2022-2023 | |
| Janssen Biotech, INC. | $46.80 | 2023-2025 | Tecvayli, Talvey, Erleada |
| Genzyme Corporation | $44.25 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.81 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunocore Limited | $40.66 | 2025 | Kimmtrak |
| Pfizer INC. | $39.29 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $34.14 | 2022 | |
| Aveo Pharmaceuticals, INC. | $27.33 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.83 | 2023 | Imbruvica, Epkinly |
| Geron Corporation | $24.43 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $24.32 | 2024 | Libtayo |
| Exelixis INC. | $24.02 | 2025 | Cabometyx |
| Genmab U.S., INC. | $22.13 | 2025 | Epkinly |
| Iovance Biotherapeutics, INC. | $21.18 | 2025 | Amtagvi |
| Tersera Therapeutics LLC | $20.71 | 2025 | Zoladex |
| Adc Therapeutics America, INC. | $19.25 | 2024 | |
| Accord Healthcare, INC. | $18.37 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.62 | 2024 | Iclusig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tri Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.